Please enable JavaScript.
Coggle requires JavaScript to display documents.
AKR1B1 (types (anti cancer (2dg (lower akr1b1 (more resistant (MG132 and…
AKR1B1
types
anti cancer
2dg
lower akr1b1
more resistant
Tolrestat and Fidarestat prove this
MG132 and bortezomib
increase NRF2
cisplatin
DRC
doxo
cells resistant to Doxorubicin
AKR1B1 was high
converts it to less toxic compound
Vincristine and 5-aza-dC
increased AKR1B1
diabete
inhibitor
epalerstat
suprres invasion
reduce pgfa2
proteasome inhibitors
MG132 and bortezomib
cancer drugs
sensitivity
AKR1B1 expression
more sensitive
resistance
higher expression akr1b1
more resistant
DRC
doxo
lower AKR1B1 expression
more resistant
2dg
higher less resistant
other drugs
Epalrestat
AKR1B1 inhibitor
restored the E-cadherin
suppression of invasion and migration
obstacles